Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 18/20 | 0.47 |
| ▸ | CTSK | P43235 | 17/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL269285 | 0.89 | CTSS (0.56) | MAPTSMN1; SMN2CTSSCTSKCTSB | |
| SCHEMBL268270 | 0.86 | CTSS (0.57) | MAPTSMN1; SMN2CTSSCTSKCTSB | |
| SCHEMBL4614298 | 0.86 | NPC1 (0.40) | MAPTCTSSCTSKCTSBCTSL | |
| SCHEMBL269354 | 0.82 | CTSS (0.60) | CTSSCTSKCTSBCTSL | |
| SCHEMBL269628 | 0.80 | JAK3 (0.48) | MAPTSMN1; SMN2CTSSCTSKCTSB | |
| SCHEMBL4925245 | 0.80 | CTSS (0.54) | CTSSCTSKCTSBCTSL | |
| SCHEMBL4600460 | 0.79 | CTSL (0.53) | MAPTCTSSCTSKCTSBCTSL | |
| SCHEMBL6746907 | 0.78 | CTSS (0.74) | CTSSCTSKCTSBCTSL | |
| SCHEMBL3762221 | 0.78 | CTSS (0.74) | CTSSCTSKCTSBCTSL | |
| SCHEMBL3992377 | 0.78 | SCN9A (0.53) | CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133907-B2 | Type II diabetes, obesity, hyperglycemia and a lipid disorder selected from dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL and high LDL; additionally comprising metformin | ELI LILLY AND COMPANY (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1912946-B1 | PYRIDINE DERIVATIVES AS DIPEPTEDYL PEPTIDASE INHIBITORS | LILLY CO ELI (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | ELI LILLY AND COMPANY | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214616-A1 | Pyridine Derivatives as Dipeptedyl Peptidase Inhibitors | DPP4, DPP3, DPP7 | MAPT 4612/4885SMN1; SMN2 4330/4885CTSS 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.